Network pharmacology analysis and experimental validation elucidate the protective mechanisms of BYHWD against hypoxia/reoxygenation-induced endothelial cell injury.

ABSTRACT:

Objective

Acute kidney injury (AKI) is a critical clinical condition with high mortality, and specific therapeutic drugs are currently lacking. Although Buyang Huanwu Decoction (BYHWD) has shown clinical efficacy against AKI, its underlying mechanisms remain unclear. This study integrated network pharmacology, in vitro experiments, and animal models to systematically elucidate the potential targets and signaling pathways of BYHWD in treating AKI, and to validate its protective effects on hypoxia/reoxygenation (H/R)-induced endothelial cell injury and renal ischemia-reperfusion injury (IRI) in vivo.

Methods

Active components and putative targets of BYHWD were screened using network pharmacology, and their intersections with AKI-related disease targets were ident

SUBMITTER: Shi Y 

PROVIDER: S-EPMC12757250 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature